Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19632318 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Basu A, Sridharan S, Persaud S (2009) Regulation of protein kinase C delta downregulation by protein kinase C epsilon and mammalian target of rapamycin complex 2. Cell Signal 21, 1680-5 19632318
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y313-p - PKCD (human)
Orthologous residues
PKCD (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
Go 6983 phorbol ester augment treatment-induced increase
rottlerin phorbol ester augment treatment-induced increase
Go 6976 phorbol ester augment treatment-induced increase
LY294002 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester inhibit treatment-induced increase
phorbol ester PKCE (human) augment treatment-induced increase PKCE siRNA inhibits phorbol ester-induced increase
phorbol ester Rictor (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol ester Abl (human) no effect upon treatment-induced increase Abl siRNA
phorbol ester Src (human) no effect upon treatment-induced increase Src siRNA
phorbol ester Fyn (human) no effect upon treatment-induced increase Fyn siRNA
phorbol ester Lyn (human) no effect upon treatment-induced increase Lyn siRNA
phorbol ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells

T507-p - PKCD (human)
Orthologous residues
PKCD (human): T507‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
Go 6983 phorbol ester inhibit treatment-induced increase
rottlerin phorbol ester no effect upon treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase
LY294002 phorbol ester no effect upon treatment-induced increase
rapamycin phorbol ester no effect upon treatment-induced increase
phorbol ester Rictor (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol ester PDK1 (human) no effect upon treatment-induced increase PDK1 siRNA
phorbol ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells

S645-p - PKCD (human)
Orthologous residues
PKCD (human): S645‑p, PKCD (mouse): S643‑p, PKCD iso2 (mouse): S669‑p, PKCD (rat): S643‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
Go 6983 phorbol ester no effect upon treatment-induced increase
rottlerin phorbol ester no effect upon treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase
LY294002 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester inhibit treatment-induced increase
phorbol ester Rictor (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol ester PDK1 (human) no effect upon treatment-induced increase PDK1 siRNA
phorbol ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells

S664-p - PKCD (human)
Orthologous residues
PKCD (human): S664‑p, PKCD (mouse): S662‑p, PKCD iso2 (mouse): S688‑p, PKCD (rat): S662‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
LY294002 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester inhibit treatment-induced increase
phorbol ester Rictor (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.